Asceneuron to attend the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis in San Francisco, CA.

by | Nov 10, 2016 | Event

Asceneuron to attend the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis in San Francisco, CA.

The 35th Annual J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends.

Click here to learn more about JP Morgan conferences

Posted :

Asceneuron will present a poster on the M1 PAM program at the Society for Neuroscience (SfN) Annual Meeting 2016 on November 12-16, 2016 in San Diego, USA.

by | Oct 19, 2016 | Event

Asceneuron will present a poster on the M1 PAM program at the Society for Neuroscience (SfN) Annual Meeting 2016 on November 12-16, 2016 in San Diego, USA.

The poster will be presented November 16, 2016, at 2:00 PM:

Session: 786 – Pharmacology for Alzheimer’s Disease Therapeutics
786.10. Estimating receptor occupancy requirements for positive allosteric modulators of the M1 muscarinic acetylcholine receptor as cognitive enhancers
*D. BEHER, A. SAND, M. NÉNY, J. HANTSON, S. OUSSON, B. PERMANNE, A. QUATTROPANI, C. WIESSNER;

About Neuroscience 2016

SfN’s 46th annual meeting is the premier venue for neuroscientists to present emerging science, learn from experts, collaborate with peers, explore new tools and technologies, and advance careers.

Posted :

See the abstract
More about the event

Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 – September 2, 2016, in Munich, Germany

by | Aug 12, 2016 | Event

Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 – September 2, 2016, in Munich, Germany

Dr. Beher, CEO will lecture on O-GlcNAcase Inhibitors for Tauopathies.

The International Conference on Alzheimer’s Drug Discovery brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion.

Posted :

More about this event